The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Open accessAbstract
BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS: Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [39]
In the citing paper
“First-line nivolumab + ipilimumab treatment also produced longer OS than chemotherapy in patients with advanced NSCLC10.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“First-line nivolumab + ipilimumab resulted in a longer duration of OS than chemotherapy in patients with metastatic NSCLC, irrespective of the PD-L1 expression10,28.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“most notably the combination of pembrolizumab and axitinib (an inhibitor of vascular growth factor inhibitor) in renal cell carcinoma.15”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [15]
In the citing paper
“Moreover, the data of CheckMate-214, CheckMate-227, and CheckMate-743 indicated the superior efficacy of ipilimumab plus nivolumab over the standard targeted therapy or chemotherapy [135–137].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Cited by
Sorted by citations
Items 201–300 of 1,003
Memmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 105
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K. S., & Besse, B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0399-6 · Cited by 105
Pérol, M., Felip, E., Dafni, U. G., Polito, L., Pal, N., Tsourti, Z., Ton, T. G. N., Merritt, D., Morris, S., Stahel, R. A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.008 · Cited by 105
Self-citationFerrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub3 · Cited by 101
Drilon, A., Tan, D. S. W., Lassen, U. N., Leyvraz, S., Liu, Y., Patel, J. D., Rosen, L., Solomon, B., Norenberg, R., Dima, L., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00418 · Cited by 105
Comparative oncology: overcoming human cancer through companion animal studies
Oh, J. H., & Cho, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00977-3 · Cited by 101
Shen, L., Zhang, Y., Li, Z., Zhang, X., Gao, X., Liu, B., Wang, Y., Ba, Y., Li, N., Zhang, R., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03450-4 · Cited by 118
Huai, Q., Luo, C., Song, P., Bie, F., Bai, G., Li, Y., Liu, Y., Chen, X., Zhou, B., Sun, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15964 · Cited by 109
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Smith, S. M., WACHTER, K., Burris, H. A., Schilsky, R. L., George, D. J., Peterson, D. E., Johnson, M. L., Markham, M. J., Mileham, K. F., Beg, M. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03420 · Cited by 107
Schoenfeld, A. J., Antonia, S. J., Awad, M. M., Felip, E., Gainor, J. F., Gettinger, S. N., Hodi, F. S., Johnson, M. L., Leighl, N. B., Lovly, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2151 · Cited by 98
Self-citationIntestinal microbiota: a new force in cancer immunotherapy
Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 98
Immunotherapy: an alternative promising therapeutic approach against cancers
Gupta, S. L., Basu, S., Soni, V., & Jaiswal, R. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07525-8 · Cited by 107
Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
Prasad, V. K., & Addeo, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.001 · Cited by 100
Wang, X., Lamberti, G., Federico, A. D., Alessi, J. V., Ferrara, R., Sholl, M. L., Awad, M. M., Vokes, N. I., & Ricciuti, B. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.007 · Cited by 99
Wu, L., Ke, L., Zhang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602762 · Cited by 99
Iranzo, P., Callejo, A., Assaf, J. D., Molina, G., López-Valbuena, D., García-Illescas, D., Pardo, N., Navarro, A., Martínez‐Martí, A., Cedrés, S., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875974 · Cited by 102
Liu, J., Kong, X., Huang, T., Wang, R., Li, W., & Chen, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02048 · Cited by 93
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105
Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 93
Campochiaro, C., Farina, N., Tomelleri, A., Ferrara, R., Lazzari, C., Luca, G. D. D., Bulotta, A., Signorelli, D., Palmisano, A., Vignale, D., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.07.016 · Cited by 92
Mosca, M., Nigro, M. C., Pagani, R., Giglio, A. D., & Federico, A. D. (2023) · Biomolecules · doi:10.3390/biom13121803 · Cited by 100
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
Brozos-Vázquez, E., Díaz‐Peña, R., García, J., León‐Mateos, L., Mondelo‐Macía, P., Peña-Chilet, M., & López‐López, R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02752-z · Cited by 93
Schüler, M., Cuppens, K., Plönes, T., Wiesweg, M., Pont, B. D., Hegedűs, B., Köster, J., Mairinger, F. D., Darwiche, K., Paschen, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02965-0 · Cited by 91
Advances in the Treatment of Non–Small Cell Lung Cancer
Patel, S. A., & Weiss, J. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.010 · Cited by 92
Immunotherapy-based combinations in metastatic NSCLC
Desai, A. P., & Peters, S. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102545 · Cited by 94
Self-citationThe Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90
Ge, Z., Zhou, G., Carrascosa, L. C., Gausvik, E., Boor, P. P. C., Noordam, L., Doukas, M., Polak, W. G., Terkivatan, T., Pan, Q., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.03.003 · Cited by 90
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 98
Poels, K., van Leent, M. M. T., Reiche, M. E., Kusters, P. J. H., Huveneers, S., de Winther, M. P. J., Mulder, W. J. M., Lutgens, E., & Seijkens, T. T. P. (2020) · Cells · doi:10.3390/cells9091987 · Cited by 87
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Katipally, R. R., Pitroda, S. P., Juloori, A., Chmura, S. J., & Weichselbaum, R. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00655-9 · Cited by 87
Herzog, B. H., Baer, J. M., Borcherding, N. C., Kingston, N. L., Belle, J. I., Knolhoff, B. L., Hogg, G. D., Ahmad, F. F., Kang, L., Petrone, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8005 · Cited by 92
The next generation of immunotherapies for lung cancers
Zhao, S., Zhao, H., Yang, W., & Zhang, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01035-9 · Cited by 96
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 93
Juloori, A., Katipally, R. R., Lemons, J. M., Singh, A. K., Iyer, R. V., Robbins, J. R., George, B., Hall, W. A., Pitroda, S. P., Arif, F., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.09.052 · Cited by 87
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 101
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung CancerPreprint
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 91
Vilariño, N., Bruna, J., Bosch‐Barrera, J., Valiente, M., & Nadal, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102067 · Cited by 85
Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer
Li, S., Xu, S., Liang, X., Xue, Y., Mei, J., Ma, Y., Liu, Y., & Liu, Y. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100078 · Cited by 86
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Tan, A. C., Bagley, S. J., Wen, P. Y., Lim, M. K., Platten, M., Colman, H., Ashley, D. M., Wick, W., Chang, S. M., Galanis, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002459 · Cited by 90
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 100
A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer
Liu, L., Yan, L., Liao, N., Wu, W.-Q., & Shi, J. (2020) · Cancers · doi:10.3390/cancers12020352 · Cited by 86
Kawashima, S., Inozume, T., Kawazu, M., Ueno, T., Nagasaki, J., Tanji, E., Honobe‐Tabuchi, A., Ohnuma, T., Kawamura, T., Umeda, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003134 · Cited by 84
Zhou, Y.-J., Li, G., Wang, J., Liu, M., Wang, Z., Song, Y., Zhang, X., & Wang, X. (2023) · Blood Science · doi:10.1097/bs9.0000000000000149 · Cited by 88
Kluger, H. M., Barrett, J. C., Gainor, J. F., Hamid, O., Hurwitz, M. E., LaVallee, T. M., Moss, R. A., Zappasodi, R., Sullivan, R. J., Tawbi, H. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005921 · Cited by 91
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K. C., Florez, N., Gadgeel, S. M., Masters, G. A., Schenk, E. L., Schneider, B. J., Sequist, L. V. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02746 · Cited by 87
Sun, S., Liu, L., Zhang, J., Sun, L., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01732-z · Cited by 101
Immunotherapy for platinum-resistant ovarian cancer
Bogani, G., Lopez, S., Mantiero, M., Ducceschi, M., Bosio, S., Ruisi, S., Sarpietro, G., Guerrisi, R., Brusadelli, C., Dell'acqua, A., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.05.681 · Cited by 82
Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Konieczny, M., Musielak, B., Kocik-Krol, J., Skalniak, Ł., Sala, D., Czub, M., Magiera‐Mularz, K., Rodríguez, I., Myrcha, M., Stec, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01260 · Cited by 84
Giglio, A. D., Federico, A. D., Nuvola, G., Deiana, C., & Gelsomino, F. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01124-9 · Cited by 84
Pharmacogenomics: A Genetic Approach to Drug Development and Therapy
Qahwaji, R. M., Ashankyty, I., Sannan, N., Hazzazi, M. S., Basabrain, A. A., & Mobashir, M. (2024) · Pharmaceuticals · doi:10.3390/ph17070940 · Cited by 99
First line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 83
Perets, R., Bar, J., Rasco, D. W., Ahn, M., Yoh, K., Kim, D.-W., Nagrial, A. M., Satouchi, M., Lee, D., Spigel, D. R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.020 · Cited by 86
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Brown, L. J., Weppler, A. M., Bhave, P., Allayous, C., Patrinely, J. R., Ott, P. A., Sandhu, S. K., Haydon, A. M., Lebbé, C., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002121 · Cited by 83
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Dai, L., Jin, B., Liu, T., Chen, J., Li, G., & Dang, J. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100990 · Cited by 81
Peters, S., Cho, B. C., Luft, A. V., Alatorre-Alexander, J., Geater, S. L., Лактионов, К. К., Trukhin, D. V., Kim, S., Ursol, G., Hussein, M., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1381 · Cited by 80
Self-citationPinato, D. J., Cortellini, A., Sukumaran, A., Cole, T., Pai, M., Habib, N., Spalding, D., Sodergren, M. H., Martinez, M., Dhillon, T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08033-x · Cited by 79
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Bonanno, L., Maso, A. D., Pavan, A., Zulato, E., Calvetti, L., Pasello, G., Guarneri, V., Conte, P., & Indraccolo, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01777-8 · Cited by 81
The evolutionary legacy of immune checkpoint inhibitors
Kaushik, I., Ramachandran, S., Zabel, C., Gaikwad, S., & Srivastava, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.020 · Cited by 79
Reck, M., Ciuleanu, T., Lee, J.-S., Schenker, M., Żurawski, B. A., Kim, S., Mahave, M., Alexandru, A., Peters, S., Płużański, A., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.04.021 · Cited by 81
Self-citationAnti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
Massari, F., Mollica, V., Rizzo, A., Cosmai, L., Rizzo, M., & Porta, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1811226 · Cited by 81
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Fortes, B. H., Liou, H., & Dalvin, L. A. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316970 · Cited by 79
Zhu, Z., Jin, Y., Zhou, J., Chen, F., Chen, M., Gao, Z., Hu, L., Xuan, J., Li, X., Song, Z., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02059-y · Cited by 87
Park, R., da Silva, L. L., Cristancho, C., Riaño, I., & Saeed, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00258 · Cited by 78
Huang, Z., Su, W., Lu, T., Wang, Y., Dong, Y., Qin, Y., Liu, D., Sun, L., & Jiao, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.578091 · Cited by 79
Immune response drives outcomes in prostate cancer: implications for immunotherapy
Meng, J., Zhou, Y., Lu, X., Bian, Z., Chen, Y., Fan, S., Zhou, J., Zhang, L., 郝宗耀, Zhang, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12887 · Cited by 77
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Jessel, S., Weiss, S. A., Austin, M., Mahajan, A. K., Etts, K., Zhang, L., Aizenbud, L., Perdigoto, A. L., Hurwitz, M. E., Sznol, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836859 · Cited by 79
Chen, M., Lu, H., Copley, S. J., Han, Y., Logan, A., Viola, P., Cortellini, A., Pinato, D. J., Power, D., & Aboagye, E. O. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.089 · Cited by 77
Preet, R., Islam, M. A., Shim, J., Rajendran, G., Mitra, A., Vishwakarma, V., Kutz, C., Choudhury, S., Pathak, H. B., Dai, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58553-4 · Cited by 82
Wang, C., Ma, J., Shao, J., Zhang, S., Li, J., Yan, J., Zhao, Z., Bai, C., Yu, Y., & Li, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828560 · Cited by 80
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C. M., Yamamoto, N., Cheng, Y., Moiseyenko, V. M., Summers, Y., Vynnychenko, I. O., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.223 · Cited by 80
Self-citationDavis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2164 · Cited by 75
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 80
Zhao, Y., Ma, Y., Fan, Y., Zhou, J., Yang, N., Yu, Q., Zhuang, W., Song, W., Wang, Z. M., Li, B., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107355 · Cited by 75
Principe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M. W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584423 · Cited by 76
Neutrophil Extracellular Traps in Cancer Therapy Resistance
Shahzad, M. H., Feng, L., Su, X., Brassard, A., Dhoparee‐Doomah, I., Ferri, L. E., Spicer, J. D., & Cools‐Lartigue, J. (2022) · Cancers · doi:10.3390/cancers14051359 · Cited by 76
Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 75
Ready, N., Audigier-Valette, C., Goldman, J. W., Felip, E., Ciuleanu, T., Campelo, M. R. G., Jao, K., Barlési, F., Bordenave, S., Rijavec, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006127 · Cited by 77
Self-citationMetabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy
Lv, Y., Li, Z., Liu, S., Zhou, Z., Jinling, S., Ba, Y., Weng, S., Zuo, A., Xu, H. W., Luo, P., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02407-6 · Cited by 93
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 75
Immunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 72
Liu, C., Zhao, W., Xie, J., Lin, H., Hu, X., Li, C., Shang, Y., Wang, Y., Jiang, Y., Ding, M.-G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1115291 · Cited by 76
Kao, H., Liao, B.-C., Huang, Y., Huang, H., Chen, C., Chen, T., Hong, Y.-J., Chan, C.-Y., Chia, J., & Hong, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3025 · Cited by 70
Lucas, C. G., Mirchia, K., Seo, K., Najem, H., Chen, W., Zakimi, N., Foster, K. J., Eaton, C. D., Cady, M. A., Choudhury, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01747-1 · Cited by 72
Pi, Y., Qi, W.-C., Xia, B.-R., Lou, G., & Jin, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697083 · Cited by 67
Konen, J. M., Wu, H., & Gibbons, D. L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.006 · Cited by 73
Courtney, P. T., Yip, A. T., Cherry, D. R., Salans, M. A., Kumar, A., & Murphy, J. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8787 · Cited by 72
Zhao, W., Jiang, W., Wang, H., He, J., Su, C., & Yu, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703143 · Cited by 70
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
Decraene, B., Yang, Y., Smet, F. D., Garg, A. D., Agostinis, P., & Vleeschouwer, S. D. (2022) · Genes and Immunity · doi:10.1038/s41435-021-00161-5 · Cited by 75
Zhao, Y., Ma, Y., Zang, A., Cheng, Y., Zhang, Y., Wang, X., Chen, Z., Qu, S., He, J., Chen, C., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01445-1 · Cited by 70
Captier, N., Lerousseau, M., Orlhac, F., Hovhannisyan, N., Luporsi, M., Woff, E., Lagha, S., Feghali, P. S., Lonjou, C., Beaulaton, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55847-5 · Cited by 68
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 80
Pearson, A. D. J., Rössig, C., Lesa, G. M., Diede, S. J., Weiner, S. L., Anderson, J., Gray, J. C., Geoerger, B., Minard‐Colin, V., Marshall, L. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.029 · Cited by 68
Passaro, A., Attili, I., Morganti, S., Signore, E. D., Gianoncelli, L., Spitaleri, G., Stati, V., Catania, C., Curigliano, G., & de Marinis, F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102085 · Cited by 65
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Uruga, H., & Mino-Kenudson, M. A. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03030-8 · Cited by 69
Metadata
- Authors
- Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O’Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Universidad Complutense de Madrid (ES)
- From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology–Germans Trias i Pujol Hospital, Badalona (E.C.C.) — all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2020-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2976744492
- Cited by
- 2,823
- References
- 26
- Citations by year
- 2026: 183 · 2025: 316 · 2024: 399 · 2023: 448 · 2022: 516 · 2021: 570 · 2020: 368 · 2019: 18
- FWCI
- 154.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- ipilimumab, non-small cell lung cancer, PD-L1 expression, immune checkpoint inhibitors, combination immunotherapy, overall survival, chemotherapy, PD-1, CTLA-4, long-term benefits, PD-L1-negative tumors, stage IV lung cancer, recurrent lung cancer, immune-related adverse events, immune-related pneumonitis
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
